Articles related to CARDIAC SURGERY

In a case of asymptomatic hypertension in a young adult, detailed imaging and timely surgical intervention demonstrated significant improvements in aortic structure and function, highlighting the critical role of early diagnosis in aortic coarctation.

In this detailed case study, physicians will gain insights into the layered complexity of managing post-infarction complications, emphasizing the critical interplay between timely surgical intervention and vigilant post-operative monitoring in preserving patient outcomes.

Experience an in-depth exploration of heart failure management in Mont-Tremblant, Canada, where you’ll delve into the latest diagnostic and therapeutic advancements, gaining insights that are crucial for enhancing patient outcomes in your practice.

Johns Hopkins’ cardiac surgery team’s strategic expansion brings together globally recognized experts, enhancing our capabilities in treating complex heart conditions and advancing research in heart and lung transplantation.

In the complex landscape of post-cardiac surgery care, the incidence of new-onset PCSAF presents a significant challenge, necessitating a judicious approach to anticoagulation to prevent thromboembolic events while minimizing bleeding risks.

The study in question presents a prospective randomized trial that evaluated the efficacy and safety of percutaneous tricuspid transcatheter edge-to-edge repair (TEER) in patients with severe tricuspid regurgitation. Conducted across 65 centers in North America and Europe, 350 patients were randomized into two equal groups, with one group undergoing TEER and the other receiving conventional medical therapy. The primary composite endpoint encompassed factors such as all-cause mortality or tricuspid valve surgery, heart failure hospitalization, and improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Also evaluated were the severity of tricuspid regurgitation and the safety profile of TEER. The trial concluded with results favoring the TEER group (win ratio, 1.48; 95% CI, 1.06-2.13; P=0.02), although rates of death, tricuspid-valve surgery, and heart failure hospitalization showed no significant difference between the two groups. The TEER group exhibited a marked improvement in KCCQ scores compared to the control group (mean change 12.3±1.8 vs. 0.6±1.8; P<0.001) and a significant reduction in the severity of tricuspid regurgitation at the 30-day mark (87.0% TEER group vs. 4.8% control group with tricuspid regurgitation of no greater than moderate severity; P<0.001). The safety profile for TEER was reassuring, with 98.3% of patients […]